Analyst Ratings February 24, 2026

BofA Holds Underperform on Fulcrum Therapeutics, $7 Target Stays Despite Clinical Progress

Analyst retains bearish valuation as shares trade above both its target and InvestingPro’s fair value after encouraging pociredir trial data

By Leila Farooq FULC
BofA Holds Underperform on Fulcrum Therapeutics, $7 Target Stays Despite Clinical Progress
FULC

BofA Securities has reaffirmed an Underperform rating on Fulcrum Therapeutics (NASDAQ: FULC) and kept a $7.00 price target, even as the stock trades at $8.98 and recent 12-week data from the Phase 1b PIONEER trial showed gains in fetal hemoglobin and reductions in hemolysis markers. Other firms have more optimistic price targets, and InvestingPro provides additional research tools for investors evaluating the volatile biotech name.

Key Points

  • BofA reaffirms Underperform on Fulcrum with a $7.00 target while shares trade at $8.98, above the analyst target and InvestingPro’s Fair Value assessment.
  • Pociredir 20 mg 12-week data in 12 severe sickle cell patients showed a 12% mean HbF increase to 19%; seven patients reached a 20% HbF threshold by week 12 (unchanged from week 6); LDH and bilirubin fell -34% and -40% respectively but stayed higher than levels in healthy individuals.
  • Other analysts hold more bullish stances—Stifel: Buy, $25 target; Oppenheimer: Outperform, $15 target—and the market’s negative reaction has been partly attributed to lack of immediate financial returns.

Market snapshot

BofA Securities has reiterated its Underperform rating on Fulcrum Therapeutics, keeping a $7.00 price target on the stock. Fulcrum shares are trading at $8.98, above both the bank’s analyst target and InvestingPro’s Fair Value assessment. That divergence suggests the shares may be priced ahead of the firm’s expectations despite a substantial 194% rise over the past year.

Clinical data at a glance

The firm’s commentary followed Fulcrum’s release of 12-week data for a 20 mg dose of pociredir administered to patients with severe sickle cell disease. The dataset covers 12 patients enrolled in the study.

At week 12, mean fetal hemoglobin (HbF) increased by 12% versus baseline, bringing the cohort to a 19% mean HbF level. Seven patients reached a 20% HbF threshold by week 12 - a figure that remained unchanged from the week 6 readout.

Markers of hemolysis also moved in line with earlier measurements: lactate dehydrogenase (LDH) and bilirubin fell by 34% and 40%, respectively, compared with prior data. However, those levels remained elevated relative to healthy individuals.

Analyst posture and investor resources

Despite the clinical signals, BofA kept its Underperform recommendation and $7 price target on the shares. For investors seeking deeper analysis of Fulcrum’s valuation and growth prospects, InvestingPro offers a Pro Research Report and 10 additional ProTips intended to assist with evaluation of this volatile biotech stock.

Other sell-side views and market reaction

The company has also discussed progress in its sickle cell program during its Q4 2025 earnings call, highlighting advances for pociredir and results from the Phase 1b PIONEER trial. Not all analysts share BofA’s caution. Stifel reiterated a Buy rating with a $25.00 price target, citing a 19.3% total mean HbF outcome that it said exceeded physician expectations. Oppenheimer maintained an Outperform rating and a $15 price target, noting that recent declines in the stock appeared to reflect profit-taking rather than a change in the company’s trajectory.

Market sentiment turned negative in the wake of the updates, with at least part of the reaction attributed to the absence of immediate financial returns tied to the clinical progress. Those developments underscore Fulcrum’s current focus on advancing clinical data rather than delivering near-term financial milestones.

Context for investors

The juxtaposition of encouraging clinical results and divergent analyst valuations illustrates the uncertainty investors face with early-stage biotech names. Fulcrum’s trial data show measurable biological effects on HbF and hemolysis markers in a small cohort, but the stock’s price sits above some analyst valuations and fair value estimates, contributing to differing opinions among market participants.


Key points

  • BofA reaffirms Underperform on Fulcrum with a $7.00 price target while the stock trades at $8.98, above the analyst target and InvestingPro’s Fair Value assessment.
  • 12-week data from the 20 mg pociredir cohort (12 patients) showed a 12% mean HbF increase to 19% and reductions in LDH and bilirubin of -34% and -40% respectively; seven patients reached the 20% HbF threshold at week 12, unchanged from week 6.
  • Other analysts have more bullish stances: Stifel holds a Buy with a $25 target and Oppenheimer an Outperform with a $15 target; the market’s negative reaction has been linked to lack of immediate financial upside.

Risks and uncertainties

  • Valuation risk - share price of $8.98 exceeds BofA’s $7 target and InvestingPro’s Fair Value assessment, indicating potential overvaluation in the market; investors in the biotech and equity markets are affected.
  • Clinical sample size and durability - the 12-week dataset comes from 12 patients and shows some endpoints unchanged from week 6; outcomes in small Phase 1b cohorts may not predict larger trial performance, a concern for the biotech sector and clinical-stage investors.
  • Market sensitivity to financial vs. clinical news - negative market reaction appears tied to the absence of near-term financial gains despite clinical progress, highlighting uncertainty for healthcare and general equity markets.

Conclusion

BofA’s continued Underperform rating and $7 target reflect a conservative valuation stance despite encouraging biological activity from pociredir in a small PIONEER cohort. Divergent analyst views and investor responses underscore the tension between clinical milestones and near-term financial expectations in early-stage biotech equities.

Risks

  • Valuation risk: the stock trades above BofA’s $7 target and InvestingPro’s Fair Value assessment, suggesting potential overvaluation in the equity market.
  • Clinical data limitations: the 12-week results derive from a 12-patient cohort, and unchanged figures from week 6 raise questions about durability and generalizability for the biotech sector.
  • Market reaction risk: negative investor response tied to lack of immediate financial gains could increase volatility for healthcare and biotech stocks.

More from Analyst Ratings

Wedbush lifts Arvinas price target to $11, cites pipeline momentum despite weak Q4 results Feb 24, 2026 Fulcrum Therapeutics Shares Slide After PIONEER 12-Week Data Miss Clinical Threshold Feb 24, 2026 RBC Capital Lifts Ferguson Price Target to $271 Citing Positioning and Market Opportunity Feb 24, 2026 RBC Lowers Ziff Davis Price Target After Mixed Q4; Keeps Outperform Rating Feb 24, 2026 RBC Lifts Galapagos Target to $33 as Company Repositions; Shares Trade Above New Mark Feb 24, 2026